Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice

References

• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688–700.
   PubMed Web of Science ®Google Scholar
• Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology. 2003;61:750–6.
   PubMed Web of Science ®Google Scholar
• Horner RD, Kamins KG, Feussner JR, Grambow SC, Hoff-Lindquist J, Harati Y, . Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology. 2003;61:742–9.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Thun MJ, Cudkowicz M, . Prospective study of military service and mortality from ALS. Neurology. 2005;64: 32–7.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:191–206.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Sims KB, Xin WW, Kiely R, O'Neill G, Ravits J, . Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:62–73.
   PubMed Web of Science ®Google Scholar
• Brown RH Jr, Robberecht W. Amyotrophic lateral sclerosis: pathogenesis. Semin Neurol. 2001;21:131–9.
   PubMed Web of Science ®Google Scholar
• Newbery HJ, Abbott CM. Of mice, men and motor neurons. Trends Mol Med. 2002;8:88–92.
   PubMed Web of Science ®Google Scholar
• Choudry RB, Cudkowicz ME. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. J Clin Pharmacol. 2005;45:1334–44.
   PubMed Web of Science ®Google Scholar
• McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs. 2005;19:31–7.
   PubMed Web of Science ®Google Scholar
• Ryu H, Ferrante RJ. Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Rev Med Chem. 2007;7:141–50.
   PubMed Web of Science ®Google Scholar
• Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, . Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;93:1087–98.
   PubMed Web of Science ®Google Scholar
• Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65 (Suppl 1):S3–9.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Traynor BJ, Cudkowicz ME. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007;12:229–52.
   PubMed Web of Science ®Google Scholar
• Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J Neurochem. 2002;80:616–25.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J, Rene F, Oudart H, . Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One. 2009;4:5390.
   PubMed Web of Science ®Google Scholar
• Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998;18: 3241–50.
   PubMed Web of Science ®Google Scholar
• Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, . Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74–8.
   PubMed Web of Science ®Google Scholar
• Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, . An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105–16.
   PubMed Web of Science ®Google Scholar
• Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, . Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron. 2004;43:19–30.
   PubMed Web of Science ®Google Scholar
• Mattiazzi M, D'Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF, . Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem. 2002;277:29626–33.
   PubMed Web of Science ®Google Scholar
• Kaal EC, Vlug AS, Versleijen MW, Kuilman M, Joosten EA, Bar PR. Chronic mitochondrial inhibition induces selective motor neuron death in vitro: a new model for amyotrophic lateral sclerosis. J Neurochem. 2000;74:1158–65.
   PubMed Web of Science ®Google Scholar
• Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve. 2006;33: 598–608.
   PubMed Web of Science ®Google Scholar
• Dhaliwal GK, Grewal RP. Mitochondrial DNA deletion mutation levels are elevated in ALS brains. Neuroreport. 2000;11:2507–9.
   PubMed Web of Science ®Google Scholar
• Gajewski CD, Lin MT, Cudkowicz ME, Beal MF, Manfredi G. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. Exp Neurol. 2003;179:229–35.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Parks JK, Cassarino DS, Trimmer PA, Miller SW, Maguire DJ, . Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol. 1998;153:135–42.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464–8.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38:73–84.
   PubMed Web of Science ®Google Scholar
• Connolly GP, Duley JA. Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci. 1999;20:218–25.
   PubMed Web of Science ®Google Scholar
• Geiger A, Yamasaki S. Cytidine and uridine requirement of the brain. J Neurochem. 1956;1:93–100.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, . Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Med. 2004;6:87–92.
   PubMed Web of Science ®Google Scholar
• Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, . Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiol Dis. 2006;24:455–65.
   PubMed Web of Science ®Google Scholar
• Saydoff JA, Liu LS, Garcia RA, Hu Z, Li D, von Borstel RW. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Res. 2003;994:44–54.
   PubMed Web of Science ®Google Scholar
• Fornai F, Busceti CL, Ferrucci M, Lazzeri G, Ruggieri S. Is there a role for uridine and pyrimidine nucleosides in the treatment of vascular dementia? Funct Neurol. 2002;17:93–9.
   PubMed Web of Science ®Google Scholar
• Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res. 2008;62: 206–9.
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Regan M, Ulus I, Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol. 2000;60:989–92.
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr, Konradi C. Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology. 2004;47 (Suppl 1):47–60.
   PubMedGoogle Scholar
• Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59: 1116–27.
   PubMed Web of Science ®Google Scholar
• Jensen JE, Daniels M, Haws C, Bolo NR, Lyoo IK, Yoon SJ, . Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients. Exp Clin Psychopharmacol. 2008;16:199–206.
   PubMed Web of Science ®Google Scholar
• Lin Z, Richards SM, Rosenfeldt FL, Pepe S. Uridine preserves ATP during hypoxic perfusion of the rat heart. Asia Pacific Heart. 1997;6:190–6.
   Google Scholar
• Aussedat J. Effect of uridine supply on glycogen resynthesis after ischemia in the isolated perfused rat heart. Cardiovasc Res. 1983;17:145–51.
   PubMed Web of Science ®Google Scholar
• Peters GJ, van Groeningen CJ, Laurensse EJ, Lankelma J, Leyva A, Pinedo HM. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites. Cancer Chemother Pharmacol. 1987;20: 101–8.
   PubMed Web of Science ®Google Scholar
• Bogdanov MB, Beal MF, McCabe DR, Griffin RM, Matson WR. A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. Free Radic Biol Med. 1999;27: 647–66.
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr. 2009;29:59–87.
   PubMed Web of Science ®Google Scholar
• Olgun A, Akman S. Mitochondrial DNA-deficient models and aging. Ann N Y Acad Sci. 2007;1100:241–5.
   PubMed Web of Science ®Google Scholar
• Shanks RD, Robinson JL. Embryonic mortality attributed to inherited deficiency of uridine monophosphate synthase. J Dairy Sci. 1989;72:3035–9.
   PubMed Web of Science ®Google Scholar
• Cansev M, Watkins CJ, van der Beek EM, Wurtman RJ. Oral uridine-5′-monophosphate (UMP) increases brain CDP-choline levels in gerbils. Brain Res. 2005;1058:101–8.
   PubMed Web of Science ®Google Scholar
• Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem. 1994;140:1–22.
   PubMed Web of Science ®Google Scholar
• Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Res Rev. 2006;52:389–97.
   PubMedGoogle Scholar
• Ipata PL, Barsotti C, Tozzi MG, Camici M, Balestri F. Metabolic interplay between intra- and extra-cellular uridine metabolism via an ATP driven uridine-UTP cycle in brain. Int J Biochem Cell Biol. 2010.
   Web of Science ®Google Scholar
• Kabadi SV, Maher TJ. Effect of uridine (U), melatonin (MLT) and ramelteon (RMT) on edema formation following traumatic brain injury (TBI) in rats. FASEB J. 2009;23 (1 MeetingAbstracts):938.14.
   Web of Science ®Google Scholar
• Zhao Q, Marolewski A, Rusche JR, Holmes GL. Effects of uridine in models of epileptogenesis and seizures. Epilepsy Res. 2006;70:73–82.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Shatskikh T, Marolewski A, Rusche JR, Holmes GL. Effects of uridine on kindling. Epilepsy Behav. 2008;13: 47–51.
   PubMed Web of Science ®Google Scholar
• Carlezon WA, Pliakas AM, Parow AM, Detke MJ, Cohen BM, Renshaw PF. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry. 2002;51:882–9.
   PubMed Web of Science ®Google Scholar
• Carlezon WA Jr, Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry. 2005;57:343–50.
   PubMed Web of Science ®Google Scholar
• DiMauro S, Hirano M, Schon EA. Mitochondrial Medicine. Abingdon, Oxon, United Kingdom: Informa Health Care; 2006.
   Google Scholar
• Gibson GE, Ratan RR, Beal MF. Mitochondria and oxidative stress in neurodegenerative disorders. Preface. Ann N Y Acad Sci. 2008;1147:11–12.
   Web of Science ®Google Scholar
• Wang L, Pooler AM, Albrecht MA, Wurtman RJ. Dietary uridine-5′-monophosphate supplementation increases potassium-evoked dopamine release and promotes neurite outgrowth in aged rats. J Mol Neurosci. 2005;27:137–45.
   PubMed Web of Science ®Google Scholar
• Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 (corrected). Neuroscience. 2005;134:207–14.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Katz J, Moore DH, O'Neill G, Glass JD, Mitsumoto H, . Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009.
   Google Scholar
• Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, . Phase II study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009;10: 99–106.
   PubMed Web of Science ®Google Scholar
• Aguirre N, Beal MF, Matson WR, Bogdanov MB. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radic Res. 2005;39:383–8.
   PubMed Web of Science ®Google Scholar
• Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, . Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med. 2000;29:652–8.
   PubMed Web of Science ®Google Scholar
• Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, . Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9:177–83.
   PubMed Web of Science ®Google Scholar
• Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, . Creatine in Huntington's disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006;66:250–2.
   PubMed Web of Science ®Google Scholar
• Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, . Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta. 2006;1762:616–26.
   PubMed Web of Science ®Google Scholar
• DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochim Biophys Acta. 2006;1762:1139–49.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, . Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999;5:347–50.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, . Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064–74.
   PubMed Web of Science ®Google Scholar